Baxter International Inc. ($BAX) Stock Forecast: Down 21.0% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a healthcare company that focuses on products to treat hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The overall market sentiment for healthcare stocks has been mixed recently, with investors closely monitoring earnings reports for growth indicators.

Why is Baxter International Inc. going down?

BAX stock is down 21.0% on Jul 31, 2025 17:06

• Baxter International Inc. (BAX) experienced a significant bearish movement following its Q2 earnings report, where it missed both earnings and sales expectations.
• The company also revised its full-year EPS outlook downwards, leading to a lack of confidence among investors and a sharp decline in the stock price.
• The weaker gross margin reported by Baxter further added to the negative sentiment, causing shares to slide nearly 9% pre-market.
• The disappointing earnings results and lowered guidance suggest that Baxter may be facing challenges in its core segments, impacting investor perception and leading to the bearish market movement.

BAX Price Chart

BAX Technical Analysis

BAX News

BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down

Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.

https://www.zacks.com/stock/news/2644517/bax-stock-falls-following-q2-earnings-sales-miss-25-eps-view-down

Stay Ahead of the Game With Baxter ( BAX ) Q2 Earnings: Wall Street's Insights on Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

https://www.zacks.com/stock/news/2638335/stay-ahead-of-the-game-with-baxter-bax-q2-earnings-wall-streets-insights-on-key-metrics

Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?

BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.

https://www.zacks.com/stock/news/2629717/baxter-q2-preview-can-core-segments-deliver-another-solid-quarter

Trending Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.0% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 7.2% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.2% Today

MercadoLibre Inc. ($MELI) Stock Forecast: Up 3.3% Today

Baxter International Inc. Price History

07.10.2024 - BAX Stock was up 0.3%

• Baxter's stock experienced a strong bullish movement today due to positive expectations regarding its third-quarter earnings.
• The surge in Baxter's stock can be attributed to the anticipated favorable Q3 earnings driven by strong product demand, positive pricing impact, and recent new product introductions.
• Despite possible cost increases from supply chain challenges, investors remain positive about Baxter's future performance, contributing to the upward movement in the stock price.
• Investors are keenly interested in analyzing key metrics and the company's overall performance in addition to traditional revenue and EPS estimates to gain a comprehensive view of Baxter's financial well-being.

08.10.2024 - BAX Stock was down 5.0%

• Despite exceeding third-quarter expectations in terms of earnings and sales, Baxter faced a stock decline due to reduced gross and operating margins.
• The aftermath of Hurricane Helene is predicted to have a financial impact on Baxter in the short term, potentially causing unease among investors and contributing to the downward movement.
• While a strong demand and favorable pricing environment were projected to boost Baxter's Q3 earnings, complications in the supply chain likely led to increased expenses, influencing the stock's drop.
• Investors, looking beyond revenue and EPS, may have lingering concerns about Baxter's future performance despite surpassing earnings estimates, which has added to the overall bearish sentiment in the market.

31.06.2025 - BAX Stock was down 21.0%

• Baxter International Inc. (BAX) experienced a significant bearish movement following its Q2 earnings report, where it missed both earnings and sales expectations.
• The company also revised its full-year EPS outlook downwards, leading to a lack of confidence among investors and a sharp decline in the stock price.
• The weaker gross margin reported by Baxter further added to the negative sentiment, causing shares to slide nearly 9% pre-market.
• The disappointing earnings results and lowered guidance suggest that Baxter may be facing challenges in its core segments, impacting investor perception and leading to the bearish market movement.

31.06.2025 - BAX Stock was down 19.7%

• The bearish movement in Baxter's stock today could be attributed to the market's reaction to the upcoming Q2 earnings report.
• Investors might be concerned about Baxter's ability to meet Wall Street's expectations for key metrics and deliver another solid quarter.
• The uncertainty surrounding the company's core segments' performance and the pressure to achieve modest growth could have contributed to the negative sentiment in the market.
• Traders might be reacting to the possibility of margin gains stabilizing after a recent recovery, which could impact Baxter's overall financial outlook and future growth prospects.

08.10.2024 - BAX Stock was down 5.1%

• Baxter surpassed expectations in its third-quarter financial performance, exceeding both earnings and sales forecasts. However, the stock declined as gross and operating margins contracted.
• The company's financial outlook was affected by Hurricane Helene's aftermath, raising concerns about its short-term prospects.
• While higher demand and pricing were anticipated to boost earnings, supply-chain challenges increased costs, influencing the stock's negative movement.
• Investors may have reacted poorly to the mix of positive financial results with margin contraction, contributing to the stock's bearish direction.

08.04.2025 - BAX Stock was up 5.3%

• The decline in short interest suggests growing investor confidence in Baxter Intl's future outlook.
• The positive market sentiment might be influenced by recent progress in healthcare, including treatment advancements and successful clinical trials.
• Investors could also be responding favorably to Baxter Intl's financial performance and strategic moves aimed at fostering growth.
• In summary, today's bullish movement in Baxter Intl's stock seems to stem from both reduced short interest and positive industry trends.

20.01.2025 - BAX Stock was up 8.9%

• Baxter's strong bullish movement today can be attributed to the better-than-expected Q4 adjusted EPS results, which exceeded both consensus estimates and the company's own guidance. This positive earnings report indicates that the company is performing well and has a solid financial outlook.
• The optimistic forecast for 2025 sales growth and adjusted EPS further boosted investor confidence in Baxter's future prospects, leading to increased buying interest in the stock.
• Despite the Q1 2025 EPS being projected below analyst estimates, the overall positive sentiment surrounding Baxter's performance and outlook likely overshadowed this minor concern, driving the stock price higher.
• Overall, Baxter's impressive financial results and optimistic guidance have propelled the stock to a bullish trajectory, reflecting investor optimism and confidence in the company's growth potential.

02.04.2025 - BAX Stock was down 5.0%

• Baxter exceeded sales expectations for medical devices in Q1, surpassing both internal projections and analyst forecasts.
• The optimistic guidance for 2025 should have instilled confidence in the company's future growth trajectory.
• Market volatility and unpredictability likely influenced profit-taking or broader concerns, leading to a decline in Baxter's stock value.
• Investor reactions to market conditions may have overshadowed the company-specific positive news, contributing to the stock's downward movement.

13.07.2024 - BAX Stock was down 6.7%

• The recent divestment of Baxter International's renal care and acute therapies business may have sparked concerns among investors, impacting the stock's performance negatively.
• Despite surpassing Q2 expectations and adjusting its outlook, the decision to divest its kidney care unit could have prompted a tepid market reaction, creating uncertainty about the company's financial future.
• External factors like Home Depot's disappointing outlook and escalating tensions in the Middle East might have compounded the bearish market sentiment, affecting Baxter International's stock price as well.
• Investor apprehension regarding Baxter's growth prospects post-divestiture led to a sell-off in the stock, with lingering doubts about its ability to sustain growth.

13.07.2024 - BAX Stock was down 6.4%

• The company faced a sharp decline in its stock value after announcing the sale of its Kidney Care unit, Vantive, to The Carlyle Group for $3.8 billion.
• Market sentiment turned negative following this announcement, with concerns arising about the potential impact of divesting such a significant segment.
• Investors seem unsure about Baxter International Inc.'s future growth trajectory without its kidney care division, prompting a selloff of shares.
• While the sale could signify a strategic realignment for Baxter, the initial market reaction appears cautious and doubtful.

13.07.2024 - BAX Stock was down 7.2%

• Baxter International's decision to sell off its renal care and acute therapies division indicates a shift in its focus, potentially sparking concerns among investors regarding future growth.
• The acquisition of Baxter's kidney-care spinoff Vantive by Carlyle Group for $3.8 billion could be causing uncertainty among investors about its impact on Baxter's finances and overall business strategy.
• Factors such as negative guidance from Home Depot and escalating tensions in the Middle East are influencing the broader market sentiment, potentially contributing to the downturn in Baxter's stock.
• In light of these strategic changes and external market conditions, investors might be reassessing their positions in Baxter International, resulting in downward pressure on the stock.

06.07.2024 - BAX Stock was up 6.9%

• Baxter International Inc. (BAX) experienced a strong bullish movement today.
• The bullish market movement can be attributed to Baxter's better-than-expected second-quarter earnings and sales, reflecting solid demand for its medically essential products.
• The company beat analyst estimates for both earnings per share (EPS) and revenue for Q2 2024, leading to a positive outlook and an increase in its full-year EPS guidance.
• The strong performance across all segments, particularly in pharmaceuticals, contributed to exceeding sales growth expectations, driving investor confidence and pushing the stock price higher.